PMID- 33834631
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 43
IP  - 5
DP  - 2021 Oct
TI  - Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase 
      inhibitor-discontinuation" in chronic myeloid leukemia.
PG  - 1110-1116
LID - 10.1111/ijlh.13528 [doi]
AB  - BACKGROUND: Leukemic stem cells (LSCs) of chronic myeloid leukemia (CML), 
      persisting in the bone marrow (BM) niche, could be responsible for the relapses 
      within the patients of whom the treatment-free remission (TFR) had been 
      attempted. We assessed the presence of the CML LSCs in the peripheral blood (PB) 
      and concurrently in the BM in the patients with chronic-phase CML (CP CML). 
      PATIENTS AND METHODS: Thirty-eight patients with CP CML were included into the 
      study. CD45(+) /CD34(+) /CD38(-) cells with positive CD26 expression were 
      considered as CML LSCs (CD26(+) LSC) by using multiparameter flow cytometry 
      (FCM). RESULTS: Mean BCR-ABL, PB LSC, and BM LSC were 58.528 IS (37.405-83.414 
      IS), 237.5 LSC/muL (16-737.5 LSC/muL), and 805 LSC/10(6)  WBCs 
      (134.6-2470 LSC/10(6)  WBCs), respectively, in newly diagnosed CML patients. In 
      the patients with BCR-ABL positive hematopoiesis, mean BCR-ABL, PB LSCs, and BM 
      LSCs were 30.09 IS (0.024-147.690 IS), 13.5 LSC/muL (0-248.7 LSC/muL) and 
      143.5 LSC/10(6)  WBCs (9-455.2 LSC/10(6)  WBCs), respectively. No CML LSCs were 
      detected in PB of patients who achieved deep molecular response (DMR). BM LSCs of 
      the patients who were in DMR were 281.1 LSC/10(6)  WBCs (3.1-613.7 LSC/10(6) 
       WBCs). The amount of PB LSCs was highest in patients with newly diagnosed CML 
      (P < .001). CONCLUSION: LSCs persisted in the BM of the patients with DMR, 
      whereas there was no LSCs in the peripheral blood. The investigation of the CML 
      LSCs in bone marrow before deciding TKI discontinuation could be justified to 
      achieve and maintain stable TFR.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Ilhan, Osman
AU  - Ilhan O
AD  - Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
FAU - Narli Ozdemir, Zehra
AU  - Narli Ozdemir Z
AUID- ORCID: 0000-0003-3237-320X
AD  - Department of Hematology, Ministry of Health Ankara City Hospital, Ankara, 
      Turkey.
FAU - Dalva, Klara
AU  - Dalva K
AD  - Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
FAU - Arslan, Aysenur
AU  - Arslan A
AD  - Department of Hematology, Ege University School of Medicine, Izmir, Turkey.
FAU - Okay Ozgeyik, Mufide
AU  - Okay Ozgeyik M
AD  - Department of Hematology, Ministry of Health Eskisehir City Hospital, Eskisehir, 
      Turkey.
FAU - Ipek, Senay
AU  - Ipek S
AD  - Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
FAU - Saydam, Guray
AU  - Saydam G
AD  - Department of Hematology, Ege University School of Medicine, Izmir, Turkey.
FAU - Haznedaroglu, Ibrahim C
AU  - Haznedaroglu IC
AD  - Department of Hematology, Hacettepe University School of Medicine, Ankara, 
      Turkey.
LA  - eng
GR  - 54173265/Pfizer/
PT  - Journal Article
DEP - 20210409
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Marrow/*drug effects/pathology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Stem Cells/*drug effects/pathology
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
OTO - NOTNLM
OT  - CML
OT  - flow cytometry
OT  - stem cell
EDAT- 2021/04/10 06:00
MHDA- 2021/11/30 06:00
CRDT- 2021/04/09 06:50
PHST- 2021/03/03 00:00 [revised]
PHST- 2020/12/24 00:00 [received]
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/04/09 06:50 [entrez]
AID - 10.1111/ijlh.13528 [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2021 Oct;43(5):1110-1116. doi: 10.1111/ijlh.13528. Epub 2021 
      Apr 9.